Johnson & Johnson (JNJ)

Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.

These pharmaceutical names have what it takes amid the current crisis and for the long run.

A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.

The Holy Grail right now are the few companies thriving and that will keep going after this is over, but there are others who will rebound and some who will not.

The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.

JNJ should survive a recession and prove in demand in a health crisis.

In the 2nd of a 3-part series, Jim Cramer goes through all 30 Dow stocks to evaluate what is safe to buy and what you should sell or avoid (like the plague).

The company has grown organically and by acquisitions. It has dealt with adversity and bad news.

The answer to that question depends on several factors, so let's break them down.

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

The S&P 500 has added these companies to the Dividend Aristocrats class of 2020.

People's United Financial is a 4.5%-yielding dividend aristocrat that's on a path to continued expansion.

Boeing's new estimate for the FAA's signing off on returning the 737 MAX to commercial skies has been pushed out until summer, June or July? Is that really that bad? Perhaps... this is a positive.

Almost 200 companies are slated to report quarterly results, including 43 S&P 500 constituents.

These healthcare stalwarts look attractive for growth and income.

It looks like JNJ has its swagger back.

Having a bad game does not mean you quit forever. It just means it is time to regroup and rethink strategy.

These are the 10 reasons why we keep going up, despite all the bad news.

I have been using these down days to buy calls and then selling on the pops up the next.

These stocks are priced for total imperfection. That's just what you want.

Most important is that the Fed felt the need earlier this week to expand it's minimum offering for overnight repo operations, while also increasing the 14 day repos.

A lot of investing is just waiting until the market hates good companies.

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

The majority of the S&P 500 stocks will report in the next two weeks. Focus on individual stock picking, but keep stops tight.

There are myriad concerns across the energy complex, the most prevalent one centered around declining global growth reducing the demand for energy.

The Trump and Xi administrations are at least looking at the same page. That's more than nothing.

There is a good foundation for more positive action in the week ahead.

Before I give my recommendation I want to visit with the charts and indicators.

Both BA and JNJ appear to have made decisions in which the bottom line took precedent over what they stand for as a company.